Author information

• ¹Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada; Radiation Medicine Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada. Electronic address: aisling.barry@rmp.uhn.ca.
• ²Seattle Cancer Care Alliance, and Department of Radiation Oncology, University of Washington, Seattle, WA, USA.
• ³Department of Medical Oncology and Haematology, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
• ⁴Princess Margaret Cancer Centre, and Department of Surgery, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
• ⁵Department of Medical Imaging, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
• ⁶Department of Interventional Radiology, Northwestern University, Chicago, IL, USA.
• ⁷Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
• ⁸Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
• ⁹UCL Cancer Institute, University College London, London, UK.
• ¹⁰Department of Surgical Biotechnology, UCL Division of Surgery and Interventional Science, University College London, London, UK.
• ¹¹Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
• ¹²Radiology Department, Humanitas Clinical and Research Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
• ¹³Department of Medical Oncology, University of Washington, Seattle, WA, USA.
• ¹⁴Radiation Oncology Unit, Department of Hematology Oncology, Pontifical Catholic University of Chile, Santiago, Chile.
• ¹⁵Department of Surgery, University of Washington, Seattle, WA, USA.
• ¹⁶Department of Surgery, Royal Brisbane and Women's Hospital, University of Queensland, Brisbane, QLD, Australia.
• ¹⁷Multi-Organ Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
• ¹⁸Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada; Radiation Medicine Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
• ¹⁹UCL Cancer Institute, University College London, London, UK; Department of Medical Physics and Biomedical Engineering, University College London, London, UK.

Free PMC article

Abstract

Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.